Using Single-cell Sequencing to Explore Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
Overview
- Phase
- Not Applicable
- Intervention
- Gastroscopic biopsy
- Conditions
- Gastric Cancer
- Sponsor
- Chinese PLA General Hospital
- Enrollment
- 28
- Locations
- 1
- Primary Endpoint
- Single-cell profiling
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The goal of this study is to analyze the tumor microenvironment (TME) in gastric cancer patients treated with combined immunotherapy and chemotherapy. The main questions it aims to answer are:
- Provide profiles of TME between pre-treatment and post-treatment to gain insights into the mechanisms of immunotherapy combined with chemotherapy in advanced gastric cancer
- Investigate the crucial factors affecting treatment efficacy by comparing gastric cancer patients with varying treatment responses
Investigators
Xinxin Wang
Prof.
Chinese PLA General Hospital
Eligibility Criteria
Inclusion Criteria
- •Non-bedridden, aged 18 to 70 years old;
- •Eastern Cooperative Oncology Group (ECOG) score is 0 to 1;
- •Histologically confirmed gastric adenocarcinoma with evaluable lesions based on RECIST 1.1;
- •Advanced gastric cancer;
- •Ready for receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab
Exclusion Criteria
- •History of other malignant diseases in the last 5 years;
- •Prior chemotherapy, radiotherapy or immunotherapy;
- •Not receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab.
Arms & Interventions
Response
Advanced gastric cancer patients who have achieved complete response (CR) or partial response (PR) after receiving combined immunotherapy and chemotherapy
Intervention: Gastroscopic biopsy
Pre-treatment
Advanced gastric cancer patients prior to receiving combined immunotherapy and chemotherapy
Intervention: SOX plus PD-1 inhibitor
Pre-treatment
Advanced gastric cancer patients prior to receiving combined immunotherapy and chemotherapy
Intervention: Gastroscopic biopsy
Post-treatment
Advanced gastric cancer patients who have received 2 to 8 cycles of combined immunotherapy and chemotherapy
Intervention: SOX plus PD-1 inhibitor
Post-treatment
Advanced gastric cancer patients who have received 2 to 8 cycles of combined immunotherapy and chemotherapy
Intervention: Gastroscopic biopsy
Response
Advanced gastric cancer patients who have achieved complete response (CR) or partial response (PR) after receiving combined immunotherapy and chemotherapy
Intervention: SOX plus PD-1 inhibitor
Non-response
Advanced gastric cancer patients who have achieved stable disease (SD) or progressive disease (PD) after receiving combined immunotherapy and chemotherapy
Intervention: SOX plus PD-1 inhibitor
Non-response
Advanced gastric cancer patients who have achieved stable disease (SD) or progressive disease (PD) after receiving combined immunotherapy and chemotherapy
Intervention: Gastroscopic biopsy
Outcomes
Primary Outcomes
Single-cell profiling
Time Frame: 6 months
Single-cell transcriptome and immune repertoire sequencing